Terminated PHASE3 INTERVENTIONAL 1-arm NCT01290887

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Conditions Eosinophilic Asthma

Interventions Reslizumab

Updated 10 times since 2017 Last updated: Apr 28, 2016 Started: Jun 30, 2011 Primary completion: Jan 31, 2015 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business decision

Other terminated trials from Teva Branded Pharmaceutical Products R&D, Inc.

More terminations from Teva Branded Pharmaceutical Products R&D, Inc.

Listed as NCT01290887, this PHASE3 trial focuses on Eosinophilic Asthma and remains terminated or withdrawn. Sponsored by Teva Branded Pharmaceutical Products R&D, Inc., it has been updated 10 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Nov 2025 — Present [monthly]

Terminated PHASE3
Sep 2025 — Nov 2025 [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2022 — Jul 2024 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Jan 2021 — Jan 2022 [monthly]

Terminated PHASE3
May 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — May 2020 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Teva Branded Pharmaceutical Products R&D, Inc.

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altoona, United States , Anaheim, United States , Ashkelon, Israel , Athens, Greece , Auckland, New Zealand , Balassagyarmat, Hungary , Bangkok, Thailand , Bangor, United States , Barnaul, Russia , Batu Caves, Malaysia and 161 more locations